[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367863-105":59,"doc-detail-367863-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","symptom-prevalence-in-gastrointestinal-cancer-a-secondary-analysis-of-ipos-data","Symptom prevalence in gastrointestinal cancer - a secondary analysis of IPOS data","","Patients with gastro-intestinal (GI) cancer have a high symptom burden, but comparative evidence against other cancer types has been limited. This study quantifies symptom prevalence among people with GI cancer receiving community-based specialist palliative care. A secondary analysis uses anonymised routinely collected symptom registry data from 2020–2023 to compare symptom frequencies and severity with other cancers. Results highlight distinct patterns across pain, nausea, vomiting, appetite, and mobility.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/symptom-prevalence-in-gastrointestinal-cancer-a-secondary-analysis-of-ipos-data/367863/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/symptom-prevalence-in-gastrointestinal-cancer-a-secondary-analysis-of-ipos-data/367863.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study purpose regarding symptom burden in GI cancer?","Question",{"text":112,"@type":113},"To determine symptom prevalence for people with GI cancer receiving specialist palliative care in the community and compare it with other cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data and period were used for the analysis?",{"text":117,"@type":113},"The study performed a secondary analysis of anonymised routinely collected symptom registry data from community-based specialist palliative care between 2020 and 2023.",{"name":119,"@type":110,"acceptedAnswer":120},"Which symptoms showed notably higher prevalence in GI cancer compared with other cancers?",{"text":121,"@type":113},"Poor appetite, nausea, vomiting, and worse mobility were more prevalent in GI cancer, while pain and weakness were reported as similar in prevalence.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367863,1790206369,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Supportive Care in Cancer (2025) 33:860  \n[https://doi.org/10.1007/s00520-025-09919-3](https://doi.org/10.1007/s00520-025-09919-3)  \nSymptom prevalence in gastrointestinal cancer: a secondary analysis of IPOS data  \nElaine G. Boland1,2 · Assem Khamis2 · Khek Tjian Tay1 · Kathyrn Chater3 · Paul Taylor4 · Alison Landon5 · Joy Ross2,5 · Fliss E. M. Murtagh2  \nReceived: 12 December 2024 / Accepted: 2 September 2025 / Published online: 18 September 2025 © The Author(s) 2025  \nAbstract  \nPurpose Patients with gastro-intestinal (GI) cancer have a high symptom burden; however, comparative data to other cancers is lacking. The aim is to determine symptom prevalence for people with GI cancer receiving specialist palliative care in the community.  \nMethod Secondary analysis of anonymised routinely collected symptom registry data from those receiving community-based specialist palliative care, between 2020 and 2023.  \nResults One thousand seven hundred thirty-three patients with GI cancer received 2,332 episodes of specialist palliative care. Common symptoms were: -pain (77% prevalence in GI cancer vs 73% other cancers); with 49% reporting being moderately/severely/overwhelmingly affected in GI vs 46% in other cancers.-nausea (34% in GI cancer vs 25% other cancers); with 16% moderately/severely/overwhelmingly affected in GI vs 11% in other cancers.-vomiting (17% in GI cancer vs 11% other cancers); with 8% moderately/severely/overwhelmingly affected in GI vs 5% in other cancers.-poor appetite (77% in GI cancer vs 68% other cancers); with 56% moderately/severely/overwhelmingly affected in GI vs 46% in other cancers. poor mobility (79% in GI cancer vs 84% other cancer); with 53% moderately/severely/overwhelmingly affected in GI vs 62% in other cancers.  \nConclusion This novel study provides comparative evidence about the nature of the high symptom burden for those with GI cancer and shows that poor appetite, nausea, vomiting, and worse mobility are more prevalent compared to other cancers, while pain and weakness are of similar prevalence. The underlying reasons may relate to illness trajectory, referral timing, or other causes and need further exploration.  \nKeywords Symptom prevalence · IPOS · Gastrointestinal cancer · Specialist palliative care · Community settings  \n* Elaine G. Boland [Elaine.boland1@nhs.net](Elaine.boland1@nhs.net)  \n1 Hull University Teaching Hospitals NHS Trust, Hull, UK  \n2 Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK  \n3 York and Scarborough Teaching Hospitals NHS Foundation Trust, York, UK  \n4 St Luke’s Hospice, Centre for Health and Related Research, University of Sheffield, Sheffield, UK  \n5 St Christopher’s Hospice, Sydenham, London, UK  \nIntroduction  \nGastrointestinal (GI) cancers are a group of cancers affecting the digestive organs. According to the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10), malignant neoplasms of digestive organs (codes C15–C26) include oesophagus, stomach, small intestines, colon, recto-sigmoid, rectum, anus and anal canal, liver, bile ducts, gallbladder and pancreas [1] . GI cancers represent 26% of global cancer incidence and 35% of cancer mortality [2] . In the UK, GI cancers contribute to 21% of cancer incidence and 27.5% of cancer deaths each year [3] . Ten-year survival rates are reported between 5% and 53% across types of GI cancers [3] .  \nPatients with GI cancers experience high symptom burden toward the last year of life. In a cohort study looking at  \n11,242 patients with GI cancers, more than 50% of patients experienced moderate-severe tiredness, poor well-being, poor appetite, breathlessness, pain, and drowsiness [4] . The findings were similar in a study within an East Asian population, with fatigue, reduced oral intake, and anorexia reported as the most prevalent symptoms in patients with GI cancers towards the end of life [5] . In both studies, a reduction in sym","cbCaigqowZFAr5fE","https://ap.wps.com/l/cbCaigqowZFAr5fE","pdf",758062,"English","# Abstract\n## Purpose\n## Method\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Design and settings\n## Ethical approval","[{\"question\":\"What was the study purpose regarding symptom burden in GI cancer?\",\"answer\":\"To determine symptom prevalence for people with GI cancer receiving specialist palliative care in the community and compare it with other cancers.\"},{\"question\":\"What data and period were used for the analysis?\",\"answer\":\"The study performed a secondary analysis of anonymised routinely collected symptom registry data from community-based specialist palliative care between 2020 and 2023.\"},{\"question\":\"Which symptoms showed notably higher prevalence in GI cancer compared with other cancers?\",\"answer\":\"Poor appetite, nausea, vomiting, and worse mobility were more prevalent in GI cancer, while pain and weakness were reported as similar in prevalence.\"}]","Symptom prevalence in gastrointestinal cancer - a secondary analysis of IPOS data | PDF",1790173026,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec5990ab0d4df4a0475cd835670249c6.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a88637aaa3004e3b5c0ddfdb2791ea27.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07b3ad12b6128659a1d4be8d42d62f96.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/697dcf3ebbdca5a86839056bb6610523.webp",980,1301]